Genus Company Profile

✉ Email this page to a colleague

GENUS has twenty approved drugs.

There are twenty-two US patents protecting GENUS drugs.

There are eighty patent family members on GENUS drugs in twenty-eight countries and twenty-nine supplementary protection certificates in thirteen countries.

International Patents:	80
US Patents:	22
Tradenames:	17
Ingredients:	17
NDAs:	20
Patent Litigation for Genus:	See patent lawsuits for Genus

Subscribe to access the full database, or Sign up for a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Genus Lifesciences	YOSPRALA	aspirin; omeprazole	TABLET, DELAYED RELEASE;ORAL	205103-001	Sep 14, 2016		DISCN	Yes	No	9,987,231	See Plans and Pricing				See Plans and Pricing
Genus	HYCODAN	homatropine methylbromide; hydrocodone bitartrate	TABLET;ORAL	005213-001	Jul 26, 1988	AA	RX	Yes	No		See Plans and Pricing				See Plans and Pricing
Genus	HYDROMORPHONE HYDROCHLORIDE	hydromorphone hydrochloride	TABLET;ORAL	077471-003	Dec 9, 2009		DISCN	No	No		See Plans and Pricing				See Plans and Pricing
Genus Lifesciences	YOSPRALA	aspirin; omeprazole	TABLET, DELAYED RELEASE;ORAL	205103-002	Sep 14, 2016		DISCN	Yes	No	9,364,439	See Plans and Pricing	Y			See Plans and Pricing
Genus	CHLORPROMAZINE HYDROCHLORIDE	chlorpromazine hydrochloride	CONCENTRATE;ORAL	214542-001	Jun 2, 2021		RX	No	Yes		See Plans and Pricing				See Plans and Pricing
Genus Lifesciences	LEVOLET	levothyroxine sodium	TABLET;ORAL	021137-006	Jun 6, 2003	AB1,AB3,AB4	RX	No	No	10,406,108	See Plans and Pricing	Y			See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Delayed-release Tablets	81 mg/40 mg	➤ Subscribe	2016-10-14

Subscribe to access the full database, or Sign up for a Free Trial
Country	Patent Number	Estimated Expiration
Eurasian Patent Organization	201100313	See Plans and Pricing
Singapore	10201401695V	See Plans and Pricing
Australia	2014202776	See Plans and Pricing
Israel	247034	See Plans and Pricing
Japan	6027890	See Plans and Pricing
Australia	2009290712	See Plans and Pricing
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Sign up for a Free Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1718641	SPC/GB12/028	United Kingdom	See Plans and Pricing	PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209
1411900	122012000052	Germany	See Plans and Pricing	PRODUCT NAME: NAPROXEN MIT ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105
1685839	92292	Luxembourg	See Plans and Pricing	PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
1441735	08C0026	France	See Plans and Pricing	PRODUCT NAME: RALTEGRAVIR POTASSIUM; REGISTRATION NO/DATE: EU/1/07/436/001 20080102
1411900	C300481	Netherlands	See Plans and Pricing	PRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17901/0263-001 20101105
1411900	CA 2012 00036	Denmark	See Plans and Pricing
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.